Loading…
Reported covered position: Director of Government Affairs
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Drug Quality and Security Act
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Legislation related to Compounding Pharmacies and federal reform of the Food, Drug and Cosmetic Act related to compounding. S. 995, HR 3204.
Drug Quality and Security Act
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Legislation related to Compounding Pharmacies and federal reform of the Food, Drug and Cosmetic Act related to compounding. S. 995, HR 3204.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) via INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
2013 · first_quarter · Q1
Issues related to third-party coverages of compounded pharmacy products and Medicare/Medicaid reimbursements of same.
Legislative and Regulatory Issues related to Compounding Pharmacies (S.959 and related bills).
Source: Senate LDA
Drug Quality and Security Act
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Legislation Related to Compounding Pharmacies and federal reform of the Food, Drug and Cosmetic Act related to compounding. S. 995, HR 3204
Pharmaceutical Quality, Security, and Accountability Act
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Legislative and Regulatory Issues related to Compounding Pharmacies (S.959 and related bills).
Pharmaceutical Quality, Security, and Accountability Act
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Legislative and Regulatory Issues as they relate to compounding pharmacies: S. 959 and related bills
National Desert Storm and Desert Shield War Memorial Act
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Legislation related to Compounding Pharmacies and federal reform of the Food, Drug and Cosmetic Act related to compounding. S. 995, HR 3204.
National Desert Storm and Desert Shield War Memorial Act
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Legislation Related to Compounding Pharmacies and federal reform of the Food, Drug and Cosmetic Act related to compounding. S. 995, HR 3204
National Desert Storm and Desert Shield War Memorial Act
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Legislation related to Compounding Pharmacies and federal reform of the Food, Drug and Cosmetic Act related to compounding. S. 995, HR 3204.
To amend the Controlled Substances Act to address the use of intrathecal pumps.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
DEA Issues relating to the Controlled Substances Act, HR 3018
To amend the Controlled Substances Act to address the use of intrathecal pumps.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
DEA Issues - Controlled Substances Act related to intrathecal devices...H.R. 3018
Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
H. Con. Res. 342 - FDA Resolution S. Con. Res. 88 - FDA Resolution FDA Reform - Reform of FDAMA (Food and Drug Act Statutes)
Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
H. Con. Res. 342 S. Con. Res. 88 General Health Care Reform FDA Reform
Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Dextromethorphan Distribution Act of 2007
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Dextromethorphan Distribution Act of 2007
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Dextromethorphan Distribution Act of 2007
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Dextromethorphan Distribution Act of 2007
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Dextromethorphan Distribution Act of 2007
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Dextromethorphan Distribution Act of 2007
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Dextromethorphan Distribution Act of 2007
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Dextromethorphan Distribution Act of 2007
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Dextromethorphan Distribution Act of 2007
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Dextromethorphan Distribution Act of 2007
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Dextromethorphan Distribution Act of 2007
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Dextromethorphan Distribution Act of 2007
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Dextromethorphan Distribution Act of 2007
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Dextromethorphan Distribution Act of 2007
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Dextromethorphan Distribution Act of 2007
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Dextromethorphan Distribution Act of 2007
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Dextromethorphan Distribution Act of 2007
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Dextromethorphan Distribution Act of 2007
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
A concurrent resolution expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
A concurrent resolution expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
A concurrent resolution expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
A concurrent resolution expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
H. Con. Res. 342 S. Con. Res. 88 General Health Care Reform FDA Reform
A concurrent resolution expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
A concurrent resolution expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
A concurrent resolution expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
A concurrent resolution expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
A concurrent resolution expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
A concurrent resolution expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
A concurrent resolution expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
H. Con. Res. 342 - FDA Resolution S. Con. Res. 88 - FDA Resolution FDA Reform - Reform of FDAMA (Food and Drug Act Statutes)
Issues related to the Healthcare Reform Act as they impact compounding pharmacists.
Issues related to the Controlled Substances Act and DEA regulatory activity with respect to pharmacies.
Filing targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) via INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
2013 · fourth_quarter · 4A
Legislation related to Compounding Pharmacies and federal reform of the Food, Drug and Cosmetic Act related to compounding. S. 995, HR 3204.
Issues related to Medicare/Medicaid reimbursement of compounded medications and recommended changes to the Social Security Act.
Issues related to the Healthcare Reform Act as they impact compounding pharmacists.
Issues related to the Controlled Substances Act and DEA regulatory activity.
Filing targets: Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) via INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
2013 · fourth_quarter · Q4
Issues related to the Controlled Substances Act and DEA regulatory activity.
Issues related to Medicare/Medicaid reimbursement of compounded medications and recommended changes to the Social Security Act.
Legislation related to Compounding Pharmacies and federal reform of the Food, Drug and Cosmetic Act related to compounding. S. 995, HR 3204.
Issues related to the Healthcare Reform Act as they impact compounding pharmacists.
Filing targets: Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) via INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
2013 · third_quarter · Q3
Issues Related to the Controlled Substances Act and DEA regulatory activity
Legislation Related to Compounding Pharmacies and federal reform of the Food, Drug and Cosmetic Act related to compounding. S. 995, HR 3204
Issues Related to Medicare/Medicaid reimbursement of compounded medications and recommended changes to the Social Secutiy Act.
Issues related to the Healthcare Reform Act as they impact compounding pharmacists
Filing targets: Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) via INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
2013 · second_quarter · Q2
Legislative and Regulatory Issues as they relate to compounding pharmacies: S. 959 and related bills
Reimbursement Issues related to compounded pharmacy products and third-party coverages of those products
DEA Issues as they relate to the Controlled Substances Act and pharmacies
Health Care Reform Act and Health Care Issues as they Impact Compounding Pharmacists
Filing targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) via INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
2012 · first_quarter · Q1
Reimbursement Issues Applicable to Pharmacy Compounding
Meningitis Outbreak General Health care reform
House Energy and Commerce Oversight Activities Overseeing Compounding Pharmacies and the FDA Senate HELP Activity in Developing Compounding Legislation
INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) via INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
2012 · fourth_quarter · Q4
All issues affecting the compounding sector of the pharmacy industry
This quarter's lobbying was mostly focused on meningitis outbreak causes, solutions and legislative and regulatory options to mitigate such a tragedy from occurring in the future.
Controlled Substances Act and DEA activities affecting compounding pharmacists
Filing targets: Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) via INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
2012 · third_quarter · Q3
Drug Enforcement Administration Policies Affecting Pharmacies, including the "constructive transfer" of controlled substances
All issues - both legislative and regulatory affecting compounding pharmacies and compounding pharmacists
Issues in healthcare reform impacting compounding pharmacists
Filing targets: Drug Enforcement Administration (DEA), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) via INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
2012 · second_quarter · Q2
Issues governed by the Controlled Substances Act and the DEA
Veterinary issues impacted by pharmacy compounding
Health Care Reform - General issues affecting pharmacy
INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) via INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
2012 · first_quarter · Q1
Issues Related to the Regulation pharmacies, pharmacists and DEA Licensing. Issues related to the constructive transfer of controlled substances/drug shortages
Reimbursement for compounded medications by CMS
Issues related to Pharmacy Benefit Managers (PBMs) as they relate to compounding pharmacies
INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) via INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
2011 · fourth_quarter · Q4
DEA Issues Affecting Pharmacy/Drug Shortages
All issues impacting compounding pharmacists Online Pharmacy Safety Act of 2011 - S. 2002
Medical Issues Generally Impacting or Impacted by Compounded Medications
INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) via INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
2011 · third_quarter · Q3
General Pharmacy Issues Impacting Compounding Pharmacies
DEA Issues Impacting Pharmacies
Follow CMS Issues as Applicable to Pharmacy Billing
INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) via INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
2011 · second_quarter · Q2
Clarifying Budget Reconciliation Act/Health Care Reform Issues
DEA Issues as they Relate to Controlled Substances and "constructive delivery" of those substances
All issues as they relate to compounding pharmacists and the pharmacy industry in general
INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) via INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
2011 · first_quarter · Q1
Dietary Supplement/Food Safety Bill
Food Safety/Dietary Supplements
All pharmacy issues, especially those that directly relate to compounding practices
INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) via INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
2010 · fourth_quarter · Q4
Issues Relating to Retail/Compounding Pharmacies (FDA, DEA and other related bills)
DEA Issues as They Relate to Controlled Substances and Chain of Custody Issues
Issues Relating to Medicare and Medicaid Reimbursement of Compounded Medications
INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) via INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
2010 · third_quarter · 3A
Issues Relating to Medicare and medicaid Reimbursement for Compounded Medications
Issues Relating to the Drug Enforcement Administration and it relation to pharmacies
Health Care Reform/Budget Reconciliation as it Relates to Health care reform
INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) via INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
2010 · third_quarter · Q3
DEA Issues relating to the Controlled Substances Act, HR 3018
Health Care Reform in General and as it Relates to Budget Reconciliation
Reimbursement of Compounded Medication as it applies to Medicare and medicaid
INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) via INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
2010 · second_quarter · Q2
DEA Issues Related to Controlled SUbstances
Health Care Reform Issue as They Relate to Pharmacy
General Labeling Issues as They Apply to Pharmacy
INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) via INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
2010 · second_quarter · RA
Healthcare reform, retail and wholesale pharmacy issues; Medicare and Medicaid, DEA Issues related to the Controlled Substances Act and other issues related to the practice of compounding pharmacy.
Healthcare reform, retail and wholesale pharmacy issues; Medicare and Medicaid, DEA Issues related to the Controlled Substances Act and other issues related to the practice of compounding pharmacy.
Healthcare reform, retail and wholesale pharmacy issues; Medicare and Medicaid, DEA Issues related to the Controlled Substances Act and other issues related to the practice of compounding pharmacy.
INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) via INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
2010 · first_quarter · Q1
Budget Reconciliation Bill -Health Care Reform Provisions
Issues Related to CMS Reimbursement of Pharmacy products
Health Care Reform Legislation
INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) via INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
2009 · fourth_quarter · Q4
DEA Issues as they relate to pharmacy
Broad Health Care Reform Issues as they relate to pharmacy and compounding pharmacies
Appropriations Issues as They Relate to the FDA and Pharmacy
INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) via INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
2009 · third_quarter · Q3
Pharmacy Issues versus manufacturing issues in the context of broader healthcare reform
General Health Care Reform
Issues of CMS/Medicare Reimbursement
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) via INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
2009 · second_quarter · Q2
Broad Health Care Reform Overhaul - House and Senate
Appropriations as they relate to FDA Funding
Pharmacy Issues as they related to compounding pharmacists and pharmacy services/governance.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) via INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
2009 · first_quarter · Q1
Issues as they Relate to Pharmacy/Medicine
General Health Care Reform
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) via INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
2008 · fourth_quarter · Q4
Follow All Legislative Issues as They Relate to Independent Pharmacies/Compounding Pharmacies
H. Con. Res. 342 S. Con. Res. 88 General Health Care Reform FDA Reform
Generally Follow Medicare/Medicaid issues as they relate to payment of pharmacists
INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) via INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
2008 · third_quarter · Q3
General Issues Pertaining to Medicare and Medicaid
Issues related to pharmacies in general and compounding specifically Issues related to pharmacy products
General Issues pertaining to the export/import of pharmacy products
INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) via INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
2008 · third_quarter · RR
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
DEA Policies Affecting Pharmacies
Filing targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Pharmacy issues affecting compounding pharmacies
Filing targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Online Pharmacy Act and other issues impacting pharmacies and the legitimate practice of pharmacy
Issues related to health care/patient care impacting compounding pharmacists
Filing targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Reimbursement Issues as They Affect Pharmacy and Compounded Medications
Health Care Reform and Related Pharmacy Issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
General Health Care Reform and Impact on Pharmacies
Filing targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Issues Relating to the Reimbursement of bulk pharmaceutical active ingredients/compounded prescriptions
Filing targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Health Care Reform Implementation - Amending Existing Law regarding the practice of compounding
DEA Issues affecting compuonding pharmacists, especially the issue of the Controlled Substances Act and issues related to "constructive delivery."
CMS Issues as they relate to the coverage of compounded medications
Filing targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Health Care Reform and Budget Reconciliation as It Relates to Health Care Reform
Filing targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Issues Affecting Compounding and Community Pharmacies
Filing targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, SENATE
Pharmacy Issues in General as they apply to Compounding Pharmacists - DME, DXM and other related issues
Food Safety Measures in House and Senate as it Applies to Dietary Supplements
Filing targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, SENATE
All pharmacy issues related to the practice of compounding
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Healthcare reform, retail and wholesale pharmacy issues; Medicare and Medicaid, DEA Issues related to the Controlled Substances Act and other issues related to the practice of compounding pharmacy.
All pharmacy issues related to wholesale and retail pharmacy
DEA Issues - Controlled Substances Act related to intrathecal devices...H.R. 3018
Filing targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
All federal issues as they relate to compounding pharmacies
Lobby Issues as they Relate to reimbursement to pharmacists
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Follow Issues as related to practice of medicine and federal regulation
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Issues Relating to Estriol Compounded Medications
H. Con. Res. 342 - FDA Resolution S. Con. Res. 88 - FDA Resolution FDA Reform - Reform of FDAMA (Food and Drug Act Statutes)
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.